Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AURA Aura Biosciences	$7.00 -3.2%	$6.62	$4.34 ▼ $12.38	$363.44M	0.46	165,621 shs	118,136 shs
COGT Cogent Biosciences	$11.71 -2.3%	$9.70	$3.72 ▼ $12.97	$1.36B	0.36	2.00 million shs	1.26 million shs
ETNB 89BIO	$9.10 -0.4%	$9.92	$4.16 ▼ $11.84	$1.36B	1.28	1.51 million shs	1.55 million shs
VERA Vera Therapeutics	$21.27 -3.2%	$22.15	$18.53 ▼ $51.61	$1.40B	1.17	1.20 million shs	1.64 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AURA Aura Biosciences	-3.18%	+6.87%	+6.71%	+17.65%	-10.03%
COGT Cogent Biosciences	-2.25%	+7.83%	+1.83%	+139.96%	+37.44%
ETNB 89BIO	-0.44%	+0.89%	-13.42%	+16.97%	+19.03%
VERA Vera Therapeutics	-3.19%	+7.86%	-8.32%	+0.09%	-43.88%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AURA Aura Biosciences	2.3406 of 5 stars	3.6	0.0	3.2	3.3	0.0
COGT Cogent Biosciences	3.4273 of 5 stars	4.4	3.0	2.3	1.7	0.6
ETNB 89BIO	1.9342 of 5 stars	3.5	1.0	2.4	0.8	0.6
VERA Vera Therapeutics	3.5823 of 5 stars	4.5	3.0	1.5	4.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AURA Aura Biosciences	3.25	Buy	$22.00	214.29% Upside
COGT Cogent Biosciences	2.82	Moderate Buy	$18.70	59.69% Upside
ETNB 89BIO	3.00	Buy	$26.29	188.85% Upside
VERA Vera Therapeutics	2.90	Moderate Buy	$63.00	196.19% Upside

Current Analyst Ratings Breakdown

Latest AURA, ETNB, VERA, and COGT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
8/13/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
8/8/2025	ETNB 89BIO	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$12.00 ➝ $11.00
8/7/2025	COGT Cogent Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$29.00 ➝ $30.00
8/7/2025	VERA Vera Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$56.00 ➝ $53.00
8/6/2025	COGT Cogent Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $21.00
8/4/2025	VERA Vera Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Peer Perform
7/29/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
7/18/2025	COGT Cogent Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $22.00
7/12/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
7/10/2025	COGT Cogent Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$25.00 ➝ $29.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$3.04 per share	N/A
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	$0.41 per share	N/A
ETNB 89BIO	N/A	N/A	N/A	N/A	$3.52 per share	N/A
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	$7.34 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AURA Aura Biosciences	-$86.92M	-$1.90	N/A	N/A	N/A	N/A	-66.90%	-55.99%	N/A
COGT Cogent Biosciences	-$255.86M	-$1.78	N/A	N/A	N/A	N/A	-223.82%	-89.44%	N/A
ETNB 89BIO	-$367.08M	-$3.61	N/A	N/A	N/A	N/A	-94.48%	-80.92%	N/A
VERA Vera Therapeutics	-$152.15M	-$3.58	N/A	N/A	N/A	N/A	-46.70%	-39.46%	N/A

Latest AURA, ETNB, VERA, and COGT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	AURA Aura Biosciences	-$0.49	-$0.47	+$0.02	-$0.47	N/A	N/A
8/7/2025	Q2 2025	ETNB 89BIO	-$0.49	-$0.71	-$0.22	-$0.71	N/A	N/A
8/5/2025	Q2 2025	COGT Cogent Biosciences	-$0.55	-$0.53	+$0.02	-$0.53	N/A	N/A
8/5/2025	Q2 2025	VERA Vera Therapeutics	-$0.82	-$1.20	-$0.38	-$1.20	N/A	N/A
5/15/2025	Q1 2025	AURA Aura Biosciences	-$0.47	-$0.55	-$0.08	-$0.55	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	N/A
ETNB 89BIO	N/A	N/A	N/A	N/A	N/A
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AURA Aura Biosciences	N/A	11.06	11.06
COGT Cogent Biosciences	N/A	4.19	4.19
ETNB 89BIO	0.07	15.19	18.03
VERA Vera Therapeutics	0.16	17.03	17.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AURA Aura Biosciences	96.75%
COGT Cogent Biosciences	N/A
ETNB 89BIO	N/A
VERA Vera Therapeutics	99.21%

Insider Ownership

Company	Insider Ownership
AURA Aura Biosciences	6.30%
COGT Cogent Biosciences	7.29%
ETNB 89BIO	2.60%
VERA Vera Therapeutics	16.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AURA Aura Biosciences	50	50.27 million	47.10 million	Not Optionable
COGT Cogent Biosciences	80	113.86 million	105.56 million	Optionable
ETNB 89BIO	40	148.31 million	144.45 million	Optionable
VERA Vera Therapeutics	40	63.77 million	53.38 million	Optionable

AURA, ETNB, VERA, and COGT Headlines

Recent News About These Companies

Deutsche Bank AG Purchases 82,483 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

1 hour ago | marketbeat.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Receives $63.00 Average Price Target from Analysts

August 12 at 2:31 AM | americanbankingnews.com

JPMorgan Chase & Co. Cuts Vera Therapeutics (NASDAQ:VERA) Price Target to $53.00

August 10, 2025 | americanbankingnews.com

Cantor Fitzgerald Analysts Lower Earnings Estimates for VERA

August 10, 2025 | americanbankingnews.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Recommendation of "Moderate Buy" by Analysts

August 10, 2025 | marketbeat.com

Lifesci Capital Issues Negative Forecast for VERA Earnings

August 10, 2025 | americanbankingnews.com

FY2025 EPS Estimates for VERA Cut by Cantor Fitzgerald

August 9, 2025 | marketbeat.com

HC Wainwright Has Negative Estimate for VERA Q3 Earnings

August 9, 2025 | marketbeat.com

What is Lifesci Capital's Forecast for VERA Q3 Earnings?

August 9, 2025 | marketbeat.com

HC Wainwright Analysts Lower Earnings Estimates for VERA

August 9, 2025 | americanbankingnews.com

JPMorgan Chase & Co. Issues Pessimistic Forecast for Vera Therapeutics (NASDAQ:VERA) Stock Price

August 8, 2025 | marketbeat.com

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 8, 2025 | globenewswire.com

Vera Therapeutics Signs New Sales Agreement with TD Securities

August 8, 2025 | theglobeandmail.com

Q3 Earnings Forecast for Vera Therapeutics Issued By Wedbush

August 8, 2025 | marketbeat.com

Vera Therapeutics (VERA) to Release Quarterly Earnings on Thursday

August 7, 2025 | marketbeat.com

Vera Therapeutics (NASDAQ:VERA) Posts Earnings Results, Misses Estimates By $0.38 EPS

August 6, 2025 | marketbeat.com

Vera (VERA) Q2 Net Loss Widens 127%

August 6, 2025 | fool.com

Vera Therapeutics (NASDAQ:VERA) Shares Gap Down - What's Next?

August 5, 2025 | marketbeat.com

Wolfe Research Downgrades Vera Therapeutics (VERA)

August 5, 2025 | msn.com

Vera Therapeutics' (VERA) "Peer Perform" Rating Reaffirmed at Wolfe Research

August 5, 2025 | marketbeat.com

Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

August 5, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AURA, ETNB, VERA, and COGT Company Descriptions

Aura Biosciences NASDAQ:AURA

$7.00 -0.23 (-3.18%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$6.83 -0.17 (-2.49%)

As of 08/14/2025 07:52 PM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Cogent Biosciences NASDAQ:COGT

$11.71 -0.27 (-2.25%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$11.71 0.00 (0.00%)

As of 04:05 AM Eastern

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

89BIO NASDAQ:ETNB

$9.10 -0.04 (-0.44%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$9.10 +0.01 (+0.05%)

As of 08/14/2025 04:52 PM Eastern

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Vera Therapeutics NASDAQ:VERA

$21.27 -0.70 (-3.19%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$23.00 +1.73 (+8.13%)

As of 04:00 AM Eastern

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time